CF
XFOR icon

Cantor Fitzgerald’s X4 Pharmaceuticals XFOR Stock Holding History

Cantor Fitzgerald’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,342
Closed -$9.52K – 546
2025
Q1 		$9.52K Hold
1,342
– – ﹤0.01% 287
2024
Q4 		$29.5K Buy
+1,342
New +$21.4K ﹤0.01% 235

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cantor Fitzgerald's XFOR Position: Q2 2025 in Review

Cantor Fitzgerald sold out of X4 Pharmaceuticals (XFOR) in Q2 2025, closing a stake of 1,342 shares — an estimated $9.52K sold.

Cantor Fitzgerald first reported a position in XFOR in Q4 2024 and held it in 2 quarters. The position peaked at $29.5K in Q4 2024. 51 funds tracked by Wall St. Rank hold XFOR as of Q2 2025.

  • Cantor Fitzgerald reported no remaining X4 Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Cantor Fitzgerald sold 1,342 X4 Pharmaceuticals shares in Q2 2025, an estimated $9.52K.
  • Cantor Fitzgerald first reported a position in X4 Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Cantor Fitzgerald's X4 Pharmaceuticals position peaked at $29.5K in Q4 2024.
  • 51 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2025.

Based on Cantor Fitzgerald's 13F filing for Q2 2025, filed 14 Aug 2025.